Summary.-The toxicity produced by two courses of methotrexate separated by different intervals has been studied in matched groups of rats. The maximum degree of neutropenia reached when courses were separated by 8 days or more was no greater than that seen after a single course of methotrexate. However, when courses were separated by < 8 days, significantly greater neutropenia resulted. The degree of neutropenia following the second course of methotrexate was directly related to the level of depression of bone marrow cell numbers at the time of the second course. Conversely the anti -leukaemic effects of 2 courses of methotrexate, in terms of time of onset of leukaemia and time of death in rats transplanted with a syngeneic T-cell leukaemia, are shown to be similar when courses of methotrexate are separated by between 2 and 12 days. Thus in this system, chemotherapeutic schedules using methotrexate may be designed on the basis of minimal host toxicity without prejudicing anti-leukaemic effects.
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These results are discussed in relation to toxicity and anti-leukaemic effects observed during UKALL trials of treatment in acute lymphoblastic leukaemia.
METHOTREXATE (MTX) is one of the main chemotherapeutic agents used in the maintenance of remission in acute lymphoblastic leukaemia (ALL). It is a synthetic analogue of folate and binds strongly to dihydrofolate reductase (Bertino, Hillcoat and Johns, 1967; Blakley, 1969) . One of its principal modes of cell killing is assumed to be due to thymidine deprivation (Borsa and Whitmore, 1969) . Its inhibition of dihydrofolate reductase prevents the methylation of several metabolites, in particular the methylation of deoxyuridine monophosphate to form thymidine monophosphate, which is necessary for DNA synthesis and replication. Thus, by interfering with nucleic acid synthesis, MTX, like most cytotoxic drugs, primarily affects rapidly dividing cells.
However, the multiplicity of action of this drug is well illustrated by the work of Tattersall, Brown and Frei (1975) who showed that MTX toxicity to mice could be reduced by the administration of thymidine, whilst its anti-tumour activity was relatively unaffected.
In acute lymphoblasticleukaemia, MTX was initially used alone (Acute Leukaemia Group B, 1969; Nagao, Lampkin and Mauer, 1970) or in sequential therapy (Acute Leukaemia Group B, 1961; Saunders, Kauder and Mauer, 1967; Krivit et al., 1968) . Now it is usually given for the maintenance of remission in combination with other drugs in cyclic therapy, as for example in the St. Jude's programme (Aur and Pinkel, 1972) Childhood, 1975 and 1976) . In the UKALL Trials I and II, the only major differences in treatment were in the timing of 6-mercaptopurine and MTX administration. In the UKALL I trial, MTX was given Childhood, 1976) . One of the factors to which these different effects may be attributed is the length of time between courses of MTX.
Vogler, Mingioli and Garwood (1973) have documented a phase of accelerated myelopoiesis after MTX. The purpose of our present studies was to determine whether giving MTX during such a period of increased myeloid cell production resulted in greater myelosuppression than that caused by MTX given at other times. This was assessed by the effects on blood neutrophil numbers of different intervals between courses of MTX. These results were related to the kinetics of the bone marrow during recovery from a single course of MTX.
Following on from the first part of this study, we assessed the anti-leukaemic effects of two courses of MTX, and whether a good anti-leukaemic effect could be obtained with courses of MTX spaced sufficiently far apart to avoid cumulative myelotoxicity.
MATERIALS AND METHODS
Animals.-Adult Fl hybrid rats of Agus x PVG/c parents were used in all experiments.
In each series of experiments, animals w"ere matched for sex, age and weight.
Methotrexate treatment.-MTX (Lederle) of a single batch was used in each experiment. The plasma half-life of MTX is less than 1 h and the majority is excreted in the urine (Berlin et al., 1963) . About 85-100% is recoverable in the urine 12 h after an oral dose of MTX (Delmonte and Jukes, 1962 This concentration was found to be 10-6M, which corresponids to a dose of 0 05 mg/ 100 g body weight, assuming even distribution of MTX throughout the tissues.
The studies enumerating bone marrow cell numbers were performed using a dose of 0 08 mg/100 g body weight/injection. The experiments studying the toxic and antileukaemic effects of the interval between courses were performed using doses of 0 05 mg/ 100 g body weight/injection (moderate dose) and 0 1 mg/100 g body weight/injection (high dose).
Transplantable leukaemia.-The transplantable rat leukaemia (NDM 10) which was kindly supplied to us by Drs Ford and Roser and which is syngeneic in PVG/c rats, grows in the peritoneal cavity as an ascites tumour. It enters a leukaemic phase, and metastisizes to other body organs approximately one week after i.p. inoculation with 107 cells. This leukaemia is described by Dibley, Dorsch and Roser (1975) as having some pathophysiological similarity to human acute lymphoblastic leukaemia. The experimental animals were given 107 NDM 10 cells i.p. 3 days before the first course of MTX. The rats challenged in this way have 100% mortality at 2-3 weeks unless treated.
Bone marrow counts.-Bone marrow samples were obtained from the femora of experimental rats by removing the ends and blowing out the bone marrow under pressure from a CO2 cylinder delivered through a Pasteur pipette. The bone marrowv was then weighed before resuspension in Hepes buffered basal minimum essential medium and counting in white-cell counting fluid by phasecontrast microscopy.
Blood white cell counts.-Blood samples were taken daily between 9 am and 12 pm from the tail veins of experimental rats. The blood samples were diluted in white-cell counting fluid, and neutrophils, and total white blood cells were enumerated by phase contrast microscopy. Values are given as international units, i.e. x 109/1. Statistics. In the myelotoxicity studies, log1o means are given, following the practice of Galton (1969 
The effects of the interval between two moderate-dose courses ofMTX on subsequent neutropenia. Table II. t only due to increased rate of bone separated by more than 6 days (i.e. on Days 7, 9, 11 or 14) the weight change is no longer significant. The lowest weights were generally recorded 4 days after the second course of MTX (see Table I ). The overshoot in neutrophil recovery described in relation to Fig. 2 is tabulated for all groups of rats in Table II . An interesting point arising out of this Table is that significant reactive neutrophilia occurs in double courses separated by 2-10 days, whereas superadditive neutropenia is only seen in courses separated by 2-7 days. The time of the maximum neutrophil count is shown in Table II , and was generally 9 days after the second course of MTX. In this respect it would appear that measurement of the late overshoot in neutrophil counts following second MTX courses is the most sensitive method we have found for detecting a superadditive effect.
The effect of a third course of MTX, given 21 days after the previous course, on blood neutrophil counts The previous section showed that a 3-week interval between a first and second course of MTX resulted in identical changes in blood neutrophil counts after each course. To see if the increased neutrophil depression observed after double MTX courses would have a longterm effect on the susceptibility of the bone marrow myeloid cells to MTX, some of the groups of rats described in the previous section were subjected to a third course of MTX, 3 weeks after they had received their second course. The results are shown in Table III . These indicate that by 3 weeks recovery had occurred in all groups, and that a further course of MTX at that time produced the same pattern of neutropenia as that seen after a single course. (Table  IV) . The greatest weight loss and mortality was seen when the second course of MTX was given on Day 4. The effects of moderate dose courses of MTX at this interval were relatively small in relation to loss of body weight (Table I) .
The blood neutrophil data show that the most profound neutropenia occurs when the second course of MTX is given These values are within normal limits up to Day 7, when the blood counts become elevated. This elevation is due to both the appearance of leukaemic cells in the blood, and to a marked rise in granulocytes. Between Days 9 and 14, the number of bone marrow cells per mg weight of bone marrow becomes significantly depleted. Thus, it seems reasonable to assume that the rapid increase in blood neutrophil numbers is mainly due to release of cells from the bone marrow. The trigger for this release has not been determined. The total white blood cell count increases until the death of the animal, when it has reached levels of 200-600 x 109/1. The neutrophil count is elevated up to Day 12, when there is a reversal, and the count rapidly decreases; and at death the neutrophil count is very low when, because of the extremely high total count, neutrophil numbers are difficult to estimate accurately.
The effect of MTX on the progre&s of tran8-planted leukaemia When MTX is administered, the onset of leukaemia, as determined by the time at which the total white blood cell count reaches 30 x 109/1, is delayed, and survival is extended. An example of a typical experiment is shown in Fig. 5 Fig. 5 is the fact that the neutrophil count is still reduced on Day 9 after a single course of MTX, which is presumably due to the myelotoxicity of MTX described previously.
The onset of leukaemia, and survival times for other MTX schedules is shown in Table V. Table VI shows the statistical significance (in terms of probability, P) of the results in Table V (Craddock, 1973 For our studies of the effects on the antileukaemic activity of altering the interval between courses of MTX, we have used as our model of acute lymphoblastic leukaemia (ALL) a rat T-cell leukaemia which has been described as having some similar pathophysiological features to human ALL (Dibley et al., 1976) . However, in terms of cell division times and the proportion of cells in cycle, this rat leukaemia is different from human ALL. The rat leukaemia has a particularly rapid doubling time of 1 day (unpublished results), with a survival time of only 2-3 weeks following i.p. injection of 107 leukaemic lymphoblasts. In human ALL the leukaemic cells are not as rapidly dividing, and undergo division at a rate similar to or less than normal cells in the bone marrow: the mean generation time in ALL patients has been estimated as being 2-8 days (Clarkson, 1969) .
Thus it is possible that MTX, which principally affects active or dividing cells, would have a different anti-leukaemic effect in patients from that in the rats of our studies. However, leukaemic cells proliferate faster when many cells have been killed by therapy and their concentration has been reduced (Clarkson, 1969) . Hryniuk (1972) showed that the antileukaemic effects of MTX are proportional to the rate of cell proliferation. On these grounds MTX is more likely to be an effective drug in the maintenance of remission, which is the situation we have simulated in our experiments. Skipper et al. (1957) showed a correlation between inoculum size and curability with MTX, under favourable conditions. It was suggested that this was due to the mutation rate of leukaemic populations resulting in MTX resistance. Although the antileukaemic effects we have observed are similar over a range of treatment schedules, the best long-term schedule would be one based on minimal host toxicity. Goldin et al. (1956) showed in mice that the best schedule for early therapy is infrequent heavy doses of MTX (in his studies, every 4 days rather than daily). The same authors (Goldin et al., 1954a) had earlier shown that the greatest anti-leukaemic effects were obtained with multi-dose schedules (Days 2 + 4 + 6). However, these were achieved at the cost of high mortality from host toxicity. They overcame this problem by using even higher doses of MTX, with administration of Citrovorum factor 12 h after the administration of MTX (Goldin et al., 1954b ). Tattersall et al. (1975 reduced MTX host toxicity by thrice daily administration of thymidine, without inhibiting the anti-tumour effects. In our present study, blood neutrophils are depressed to an extent greater than that caused by a single course of MTX if a second course of MTX is given on Days 2 to 7, but not if given after 8 or more days. We also show that body weight is depressed if the second course of MTX is given on Days 2 to 6, but not if given later. However, the antileukaemic effects of MTX courses separated by 2 to 12 days are similar, and thus the courses could be spaced to give optimum anti-leukaemic effects with minimal host toxicity.
